G6PD and non-autoimmune hemolytic anemia: The long half-life (15 days)7 of tafenoquine could be a major advantage over short-lived gametocytocidal treatments, but comes with a risk of prolonged haemolysis for individuals deficient in the production of glucose-6-phosphate dehydrogenase (G6PD),8 who can have acute haemolytic anaemia after radical curative treatment of P vivax malaria with primaquine.